Literature DB >> 7689454

Fluoroquinolones: interaction profile during enteral absorption.

K M Deppermann1, H Lode.   

Abstract

Fluoroquinolones are used worldwide in the treatment of severe infections. These drugs, however, can interact with other agents. This paper is a review of drug interactions with different quinolone derivatives at the absorption phase; the review deals mainly with the prototype quinolones, ciprofloxacin and ofloxacin, and also with some of the newer agents. The concomitant agents considered are food, H2-receptor antagonists, anticholinergic drugs and metallic cation-containing compounds. Food (standard breakfast), H2-receptor antagonists and anticholinergic drugs had no major effect on the bioavailability of the quinolones. However, antacids, ferrous sulfate and other metallic cation-containing compounds impaired the bioavailability of the quinolones. This effect is due to chelation between the functional groups of the quinolone molecule and the metallic cations, resulting in insoluble complexes that can be absorbed. The degree of impairment varied between different quinolone derivatives.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689454     DOI: 10.2165/00003495-199300453-00013

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  50 in total

1.  Avidity of terramycin and aureomycin for metallic cations.

Authors:  A ALBERT
Journal:  Nature       Date:  1953-08-01       Impact factor: 49.962

2.  Effect of staggered dose of calcium on the bioavailability of ciprofloxacin.

Authors:  B M Lomaestro; G R Bailie
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  Effect of pirenzepine on oesophageal, gastric, and enteric motor function in man.

Authors:  E E Soffer; D Kumar; K Mridha; A Das-Gupta; J Britto; D L Wingate
Journal:  Scand J Gastroenterol       Date:  1988-03       Impact factor: 2.423

4.  Clinical and chemical interactions between iron preparations and ciprofloxacin.

Authors:  M Kara; B B Hasinoff; D W McKay; N R Campbell
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

5.  Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis.

Authors:  T A Golper; A I Hartstein; V H Morthland; J M Christensen
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

6.  Daily gastric pH in controls and in duodenal ulcer patients: basal condition and response to treatment.

Authors:  G Masoero; A Rossanino; W Arossa; M Marchetto; M Marucci; M De la Pierre
Journal:  Am J Gastroenterol       Date:  1988-02       Impact factor: 10.864

Review 7.  [Stress ulcer disease and its prevention].

Authors:  K Gyr; R Meier
Journal:  Schweiz Med Wochenschr       Date:  1989-04-05

8.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

9.  [Drugs modifying motility in ulcer therapy].

Authors:  P C Lederer; G Lux
Journal:  Z Gastroenterol       Date:  1987-08       Impact factor: 2.000

10.  Ranitidine influences the uptake of oral midazolam.

Authors:  R J Elwood; P J Hildebrand; J W Dundee; P S Collier
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

View more
  22 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.

Authors:  H Stass; D Kubitza
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.

Authors:  S Lober; S Ziege; M Rau; G Schreiber; A Mignot; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.

Authors:  H Stass; D Kubitza
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.

Authors:  H Stass; U Schühly; J G Möller; H Delesen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.

Authors:  H Stass; M F Böttcher; K Ochmann
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.

Authors:  J A Zix; H F Geerdes-Fenge; M Rau; J Vöckler; K Borner; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 8.  Factors influencing the bioavailability of peroral formulations of drugs for dogs.

Authors:  S Sabnis
Journal:  Vet Res Commun       Date:  1999-11       Impact factor: 2.459

Review 9.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

Review 10.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.